3-bromo-5-(1,3-dixolan-2-yl)aniline | 936844-19-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-bromo-5-(1,3-dixolan-2-yl)aniline
• 英文别名: 3-bromo-5-(1,3-dioxolan-2-yl)aniline；2-(3-amino-5-bromophenyl)-1,3-dioxolane；3-Bromo-5-[1,3]dioxolan-2-yl-phenylamine
• CAS: 936844-19-8
• 化学式: C₉H₁₀BrNO₂
• 分子量: 244.088
• InChiKey: ZWXDIAXNQUVUNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromo-5-(1,3-dixolan-2-yl)aniline 在 硫酸 、 sodium nitrite 作用下， 以 硫酸 、 水 、 溶剂黄146 为溶剂， 反应 0.58h， 生成 3-溴-5-羟基苯甲醛
  参考文献：
  名称：

  Covalent Assembly of Molecular Ladders

  摘要：

  [n]-Rung molecular ladders (n = 3-6) have been prepared by reacting discrete, complimentary m-phenylene ethynylene oligomers using imine formation/exchange. The nanostructures, which in the largest case measure approximately 1.6 x 6.2 nm, have been characterized by MALDI mass spectrometry and gel permeation chromatography. Although the ladder structure is a significant component in each case, the formation of higher molecular weight byproducts becomes more pronounced as the length increases. These structures represent an important first step toward the synthesis of larger, more sophisticated two-dimensional molecular grids.

  DOI：

  10.1021/ja0690013
• 作为产物：
  描述：

  2-(3-bromo-5-nitrophenyl)-1,3-dioxolane 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 以0.72 g的产率得到3-bromo-5-(1,3-dixolan-2-yl)aniline
  参考文献：
  名称：

  Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole

  摘要：

  GPR40 is an attractive target due to its glucose-stimulated insulin secretion effect with low risk of causing hypoglycemia, which also can be seen from the clinical studies using TAK-875 (fasiglifam). In the present studies, we discovered a series of analogues containing 3,5-dimethylisoxazole as potent GPR40 agonists, especially compound ilk with an EC50 value of 15.9 nM. Moreover, compound 11k reduced glucose excursion to 23.1% in ICR mice and 29.5% in type 2 diabetic C57BL/6 mice at 30 mg/kg. It also exhibited satisfactory PK profile. Docking studies were conducted to explain the interaction mode of this series. In summary, compound 11k with robust efficacy in vitro and in vivo is a promising drug candidate for further investigation. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.03.054

文献信息

• IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY
  申请人：Saxty Gordon

  公开号：US20120041000A1

  公开（公告）日：2012-02-16

  The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及公式（I）的新的双环杂环基衍生物，涉及包含该类化合物的药物组合物，以及利用该类化合物治疗疾病，例如癌症。
• IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY
  申请人：Astex Therapeutics Ltd.

  公开号：EP2419428B1

  公开（公告）日：2015-05-13
• US8722687B2
  申请人：——

  公开号：US8722687B2

  公开（公告）日：2014-05-13
• [EN] IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINE EN TANT QU'INHIBITEURS DE FGFR KINASES DESTINÉS À ÊTRE UTILISÉS EN THÉRAPEUTIQUE
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2010119285A1

  公开（公告）日：2010-10-21

  The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
• Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole
  作者：Lingyun Yang、Jian Zhang、Lianghui Si、Li Han、Bo Zhang、Hui Ma、Junhao Xing、Leilei Zhao、Jinpei Zhou、Huibin Zhang

  DOI：10.1016/j.ejmech.2016.03.054

  日期：2016.6

  GPR40 is an attractive target due to its glucose-stimulated insulin secretion effect with low risk of causing hypoglycemia, which also can be seen from the clinical studies using TAK-875 (fasiglifam). In the present studies, we discovered a series of analogues containing 3,5-dimethylisoxazole as potent GPR40 agonists, especially compound ilk with an EC50 value of 15.9 nM. Moreover, compound 11k reduced glucose excursion to 23.1% in ICR mice and 29.5% in type 2 diabetic C57BL/6 mice at 30 mg/kg. It also exhibited satisfactory PK profile. Docking studies were conducted to explain the interaction mode of this series. In summary, compound 11k with robust efficacy in vitro and in vivo is a promising drug candidate for further investigation. (C) 2016 Elsevier Masson SAS. All rights reserved.